Industry Suggests Increase In Spiked Supplements Reflects FDA Investment In Testing, Targeted Selection
This article was originally published in The Tan Sheet
The number of products marketed as supplements and identified as tainted in 2013 grew 136% from 2011 – the year after FDA announced it would take “swift and strong” enforcement action. Trends in recalls and public notifications likely reflect FDA’s investment in testing products, a strategy in need of updating, supplement industry trade groups say.
You may also be interested in...
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
FDA threatens to take "swift and strong" enforcement action without warning, including filing criminal charges, against manufacturers, suppliers and distributors of tainted supplements, according to a letter sent to industry Dec. 15.
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed